Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A generates $5mm for Arcturus Therapeutics

Executive Summary

Arcturus Therapeutics Inc. (RNAi-based treatments for rare orphan respiratory diseases) raised $5mm through its Series A venture round. Several investors from the US, Canada, and Japan led, with about 90% of the June 2013 seed round backers returning. The company will use the money to nominate its first clinical drug candidate next year and expand its team. Since the $1.3mm seed round, the start-up has acquired from Marina Biotech intellectual property related to an unlocked nucleobase analog platform--a gene silencing technology used to improve RNAi therapeutics while retaining their potency.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies